Estrella Immunopharma, Inc.
ESLANasdaqHealthcare · Biological Products, (No Diagnostic Substances) · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Operating income | −$13.1M | −$4.4M | −$11.1M | −$1.6M | −$249,146 |
| Net income | −$13.1M | −$4.4M | −$11.1M | −$996,104 | −$247,718 |
| Total assets | $3.2M | $3.1M | $3.0M | $9.7M | $45.8M |
| Total liabilities | $13.5M | $3.0M | $9.8M | $2.7M | $1.6M |
| Equity | −$10.4M | $4.3M | −$11.7M | −$2.3M | $0 |
| EPS (diluted) | $-0.35 | $-0.12 | $-36.35 | — | — |
| Shares out. | 36.8M | 36.2M | 2.3M | 5.8M | 1.4M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- 126.0%
- Return on assets
- −411.2%
- Return on capital (ROCE)
- —
- Liabilities / assets
- 426.3%
- Debt / equity
- —
- Book value / share
- $-0.28
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -90.89distress
- Accruals / assets
- −355.0%clean
- Piotroski F-Score
- 1/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 3 severe● 2 warning● 2 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Strong return on equity (>15%)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗May 18, 2026
- NT 10-Qmissed a reporting deadline ↗Nov 15, 2023
- NT 10-Qmissed a reporting deadline ↗May 16, 2023
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Armistice Capital, LlcPassive (13G)May 15, 2026
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Xu JiandongOfficer — Chief Financial Officer | Sep 11, 2025 | Buy | 100 | $1.04 |
| Owl Creek Asset Management, L.P.10% owner | Sep 29, 2023 | J | 255,000 | $10.86 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 94,135 | 2.7 | -36.2% |
| Apr 30, 2026 | 147,543 | 3.8 | -44.5% |
| Apr 15, 2026 | 265,805 | 1.0 | -57.6% |
| Mar 31, 2026 | 626,324 | 9.8 | -4.5% |
| Mar 13, 2026 | 656,018 | 16.8 | +2.7% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Delisting / listing-standard noticeJan 13, 2026
- Entered a material agreement · Unregistered equity sale · Regulation FD disclosureJan 6, 2026
- Other material eventDec 4, 2025
- Other material eventNov 6, 2025
- Other material eventSep 29, 2025
- Director / officer changeSep 26, 2025
- Delisting / listing-standard noticeAug 7, 2025
- Other material eventJun 5, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- DEF 14AMay 27, 2026
- 10-QQUARTERLY REPORTMay 18, 2026
- NT 10-QNOTIFICATION OF LATE FILINGMay 18, 2026
- SCHEDULE 13GMay 15, 2026
- 10-K/AAMENDMENT NO. 1 TO FORM 10-KApr 30, 2026
- 4Apr 29, 2026
- 10-KANNUAL REPORTMar 18, 2026
- 424B3PROSPECTUSFeb 13, 2026
- EFFECTJan 23, 2026
- S-1/AREGISTRATION STATEMENTJan 22, 2026
- S-1/AREGISTRATION STATEMENTJan 16, 2026
- 8-KCURREN REPORTJan 13, 2026
- 8-KCURRENT REPORTJan 6, 2026
- 424B5PROSPECTUS SUPPLEMENTJan 6, 2026
- S-1REGISTRATION STATEMENTDec 22, 2025
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.